SOURCE: TheraBiogen, Inc.

August 25, 2011 09:45 ET

Independent Scientific Study Recognizes Positive Effects of TheraMax® on Influenza Virus Infections

NEW YORK, NY--(Marketwire - Aug 25, 2011) - TheraBiogen, Inc. (OTCBB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, today announced the recent publication of an independent study by Donald F. Smee, Brett L. Hurst and Min-Hui Wong of Utah State University, published in Antiviral Chemistry & Chemotherapy 2011. The study may be viewed at http://www.intmedpress.com/journals/avcc/abstract.cfm?id=1744&pid=92.

The study suggests that components of green tea and elderberry may be beneficial in treating influenza virus infections by blocking virus absorption to cells. Combined results were in comparison to Oseltamivio (Tamiflu®). TheraMax® is a proprietary medication administered by nasal spray that contains both green tea and elderberry extracts that was evaluated for antiviral activity.

Kelly T. Hickel, CEO of TheraBiogen, commented, "We designed the ingredients and delivery system of TheraMax® Cold & Flu to have a direct effect and be absorbed immediately." He continued, "The study's conclusion that the combined results indicate that TheraMax® delayed symptoms during animal infections, was extremely gratifying for the Company."

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com or on Facebook at facebook.com/theramaxnasalspray.

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.

Contact Information

  • Company Contact:
    TheraBiogen, Inc.
    Kelly T. Hickel
    Chairman and CEO
    646-808-3095
    Email Contact